Welcome to our dedicated page for CapsoVision news (Ticker: CV), a resource for investors and traders seeking the latest updates and insights on CapsoVision stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CapsoVision's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CapsoVision's position in the market.
CapsoVision (NASDAQ: CV), a commercial-stage medical technology company specializing in advanced imaging and AI-powered capsule endoscopy solutions, has announced the pricing of its initial public offering (IPO). The company is offering 5,500,000 shares of common stock at $5.00 per share.
Trading is set to commence on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol "CV". The offering, expected to close on July 3, 2025, aims to raise approximately $27.5 million in gross proceeds before deducting underwriting costs and other expenses. The underwriters have a 30-day option to purchase up to 825,000 additional shares at the IPO price.
The Benchmark Company and Roth Capital Partners are serving as joint book-running managers for the offering, which will be conducted through a prospectus as part of an SEC-approved registration statement.
FAQ
What is the current stock price of CapsoVision (CV)?
